NCT06986434 2025-09-03
CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms
Affiliated Hospital to Academy of Military Medical Sciences
Phase EARLY_PHASE1 Not yet recruiting
Clinical Trials
9 trialsNCT07077330 2025-07-22
CAR19BCMA
Chinese PLA General Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT06732232 2024-12-13
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
Shanghai Cell Therapy Group Co.,Ltd
Phase EARLY_PHASE1 Recruiting
NCT06718270 2024-12-12
a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
Shanghai Changzheng Hospital
Phase EARLY_PHASE1 Recruiting
NCT06298266 2024-03-07
To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma
Guangdong Second Provincial General Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT04626752 2020-11-13
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04603872 2020-10-28
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT03661554 2018-09-10
BCMA CAR-T
The Pregene (ShenZhen) Biotechnology Company, Ltd.
Phase EARLY_PHASE1 Unknown
NCT03559764 2018-06-18
Study of BCMA CAR-T in Multiple Myeloma
Allife Medical Science and Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown